Cancer NetworkOriginal article
<![CDATA[FDA MCGP Panel Votes in Favor of the Galleri Multicancer Early Detection Test]]>
AdComGalleriPositive
AI Analysis
Summary
The FDA MCGP Panel voted in favor of the Galleri multicancer early detection test, which was evaluated based on data from the NHS-Galleri and PATHFINDER 2 studies. The panel discussed the risk-benefit profile of the test.
Clinical Trial Data
Outcome Details
FDA MCGP Panel voted in favor of the Galleri multicancer early detection test
Importance:7/10
Sentiment:
0.80
FDAAdvisory CommitteeMulticancer DetectionMCGP PanelNHS-GalleriPATHFINDER 2
Read the original article
Published by Cancer Network on September 23, 2026 9:34 PM